7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $75M | -$645M | 5.0% | -867.9% | -57.0% | -43.7% | -$378M | — | $743M |
| 2024 | $59M | -$464M | 23.1% | -814.1% | -44.8% | -32.0% | -$373M | — | $594M |
| 2023 | $45M | -$328M | 4.5% | -785.3% | -70.8% | -50.2% | -$300M | — | $392M |
| 2022 | $40M | -$239M | -21.2% | -616.7% | -49.3% | -34.1% | -$121M | — | $550M |
| 2021 | $10M | -$186M | 100.0% | -1795.8% | -34.3% | -30.6% | -$198M | $723000 | $285M |
| 2020 | $4M | -$87M | 100.0% | -2135.7% | 42.2% | -29.1% | -$51M | — | $262M |
| 2019 | $2M | -$62M | 0.0% | -2692.6% | 49.8% | — | -$61M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $8M | -$131M | -49.8% | -1759.7% | -14.3% | -10.8% | -$106M | — | $546M |
| Mar '26 | $6M | -$118M | -93.0% | -1985.6% | -11.5% | -8.8% | -$81M | — | $654M |
| Dec '25 | $36M | -$108M | 59.8% | -304.8% | -9.6% | -7.3% | -$47M | — | $743M |
| Sep '25 | $5M | -$162M | -183.8% | -3327.6% | -15.5% | -11.6% | -$118M | — | $660M |
| Jun '25 | $19M | -$172M | -4.9% | -916.8% | -18.7% | -13.2% | -$80M | — | $525M |
| Mar '25 | $15M | -$202M | -48.0% | -1297.9% | -21.7% | -15.5% | -$134M | — | $500M |
| Dec '24 | $5M | -$179M | -181.4% | -4042.4% | -17.3% | -12.4% | -$117M | — | $594M |
| Sep '24 | $26M | -$96M | 53.7% | -377.1% | -18.3% | -13.2% | -$64M | — | $428M |
| Jun '24 | $14M | -$98M | 36.2% | -697.4% | -16.7% | -12.6% | -$83M | — | $474M |
| Mar '24 | $14M | -$91M | 19.1% | -698.4% | -22.8% | -16.4% | -$109M | — | $296M |
| Dec '23 | $11M | -$93M | 9.3% | -908.4% | -20.1% | -14.2% | -$76M | — | $392M |
| Sep '23 | $11M | -$93M | -3.3% | -945.1% | -21.2% | -14.7% | -$74M | — | $387M |
| Jun '23 | $11M | -$77M | 14.8% | -741.7% | -16.4% | -11.5% | -$71M | — | $406M |
| Mar '23 | $12M | -$65M | -2.6% | -575.8% | -15.2% | -10.4% | -$78M | — | $473M |
| Dec '22 | $14M | -$57M | 20.7% | -445.9% | -11.8% | -8.2% | -$53M | — | $550M |
| Sep '22 | $13M | -$60M | -17.1% | -475.5% | -15.6% | -9.9% | -$63M | — | $455M |
| Jun '22 | $8M | -$66M | -85.4% | -862.5% | -15.0% | -9.7% | -$78M | — | $454M |
| Mar '22 | $5M | -$56M | -46.2% | -1049.7% | -11.3% | -7.6% | $73M | — | $508M |
| Dec '21 | $3M | -$65M | 100.0% | -2564.5% | -12.0% | -10.6% | -$66M | $723000 | $285M |
| Sep '21 | $3M | -$47M | 100.0% | -1831.2% | -7.9% | -7.2% | -$43M | $744000 | $395M |
How the market has priced RXRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Recursion Pharmaceuticals, Inc.'s revenue has grown 79.9% per year. These are computed facts, not advice.
As of FY2025, Recursion Pharmaceuticals, Inc. reported — of total debt against $743M of cash; operating income covered interest expense -358.1×.
In FY2025, gross margin was 5.0%, operating margin -867.9%, and net margin -863.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.